<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:chebi fb="5" ids="7872">Oxytocin</z:chebi> (<z:chebi fb="0" ids="7872">OXT</z:chebi>) pretreatment protects the heart during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury by activating ATP-dependent <z:chebi fb="120" ids="26216">potassium</z:chebi> (K(ATP)) channels </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the current study was to elucidate the roles of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthaseNOS and myocardial biochemistry in the cardioprotective effects of <z:chebi fb="0" ids="7872">OXT</z:chebi> and ischemic preconditioning (<z:chebi fb="76" ids="53004">IPC</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>MAIN METHODS: Male New Zealand White anesthetized rabbits (13 groups) were subjected to 30 min of occlusion of the left coronary artery and 120 min of reperfusion with or without <z:chebi fb="76" ids="53004">IPC</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>KEY FINDINGS: <z:chebi fb="76" ids="53004">IPC</z:chebi> (1 cycle), <z:chebi fb="0" ids="7872">OXT</z:chebi> (0.03 μg/kg, i.p.) or <z:chebi fb="76" ids="53004">IPC</z:chebi> + <z:chebi fb="0" ids="7872">OXT</z:chebi> yield significant <z:mpath ids='MPATH_124'>infarct</z:mpath> size reductions (21.8±1.5%, 20.5±1.2% and 19.4±1.4%, respectively, versus 38.9±3.5% in the S-CONT group; P&lt;0.01) and antiarrhythmic effects, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (0%, 0% and 0%, versus 50% in S-CONT group; P&lt;0.05) sustained VT (13%, 13% and 13%, versus 100% in S-CONT group; P&lt;0.005) and other <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (25%, 13% and 25%, versus 100% in S-CONT group; P&lt;0.005, P&lt;0.01 and P&lt;0.005, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>Atosiban (ATO, a selective <z:chebi fb="0" ids="7872">OXT</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>), 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (a nonspecific NOS inhibitor) abolished the beneficial effects of <z:chebi fb="76" ids="53004">IPC</z:chebi> and <z:chebi fb="0" ids="7872">OXT</z:chebi>, suggesting that the benefits are achieved via selective activation of <z:chebi fb="0" ids="7872">OXT</z:chebi> receptors, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> K(ATP) channels and NO </plain></SENT>
<SENT sid="5" pm="."><plain>An iNOS inhibitor (1400 W) blocked the beneficial effects of <z:chebi fb="76" ids="53004">IPC</z:chebi> but not <z:chebi fb="0" ids="7872">OXT</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="76" ids="53004">IPC</z:chebi>, <z:chebi fb="0" ids="7872">OXT</z:chebi>, <z:chebi fb="76" ids="53004">IPC</z:chebi> + <z:chebi fb="0" ids="7872">OXT</z:chebi> and 1400 W + <z:chebi fb="0" ids="7872">OXT</z:chebi> interventions significantly preserved ATP levels in the heart </plain></SENT>
<SENT sid="7" pm="."><plain>SIGNIFICANCE: This study demonstrates similarities between <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="0" ids="7872">OXT</z:chebi> pretreatment and <z:chebi fb="76" ids="53004">IPC</z:chebi> in terms of <z:mpath ids='MPATH_124'>infarct</z:mpath> size reduction, antiarrhythmic activity, and metabolic status </plain></SENT>
</text></document>